ClinicalTrials.gg

Program

AQUA07

A development code.

In Hoffmann-La Roche's pipeline, allosteric ALK inhibitor. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hoffmann-La Roche.

Furthest: phase 1, since May 14, 20261 company-led study, 1 open or runningNext primary completion: Aug 31, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since May 14, 2026May 14, 2026Aug 31, 2030phase 1 · NCT07617337
  • Named in Hoffmann-La Roche’s own pipeline as CHU AQUA07 allosteric ALK inhibitor, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2026First study: phase 1 study in ALK Positive Non-small Cell Lung CancerFirst studyNCT07617337 · 102 planned · United States, Japan

Ahead

  1. Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerNCT07617337

TargetBeta

“allosteric ALK inhibitor”the company's pipeline, read by Claude · source

Other programs on ALK

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
lorlatinibrulePfizerphase 420
gilteritinibruleAstellas Pharmaphase 320
ensartinibruleBetta Pharmaceuticalsphase 312
repotrectinibruleBristol-Myers Squibbphase 39
neladalkibGlaxoSmithKlinephase 32
Foritinib SuccinateFosun Pharmaphase 21
ALK Molecular Glue Degrader TRI-611ruletriana-biomedicines-incphase 21
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan1RecruitingAug 31, 2030102

How it is read

Names in the registry

  • “AQUA07”, 1 entry

Codes read as this program: AQUA07.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.